J

Johnson & Johnson

Makes prescription drugs and medical devices

Laboratory Automation Systems Intern

Summer 2027Posted on 10/23/2026Deadline 11/2/26
No salary listed
Internship
Bachelor's, Master's
Spring House, PA, USA
In PersonFully onsite in Spring House, Pennsylvania.
Data & AnalyticsData Management
No H1B Sponsorship

About the job

Requirements
  • Completion of undergraduate freshman year at an accredited university is required.
  • Currently pursuing a Bachelor's or Master's degree in Laboratory Automation, Engineering, Computer Science, Data Science, Information Systems, Life Sciences, Pharmaceutical Sciences, Digital Systems, or a related field.
  • Have a cumulative GPA of 3.0 or higher across all college coursework.
  • Strong attention to detail and ability to organize, validate, reconcile, and accurately document technical information.
  • Working knowledge of Microsoft productivity and collaboration tools, including Excel, PowerPoint, SharePoint, and/or Microsoft Teams.
  • Strong analytical, organizational, and problem-solving skills.
  • Effective written and verbal communication skills.
  • Ability to collaborate effectively with scientific, engineering, automation, operations, and IT/Digital stakeholders.
  • Ability and willingness to learn unfamiliar laboratory equipment, software, terminology, and scientific workflows.
  • Ability to manage priorities, track issues, and complete assigned activities within established timelines.
  • Ability to work independently on assigned responsibilities while contributing effectively within a cross-functional team.
  • Comfort working under supervision within laboratory environments.
  • Willingness and ability to complete required laboratory safety, EH&S, cybersecurity, data-handling, responsible AI, and site-access training.
  • Ability to follow established access controls, equipment-specific requirements, and applicable information-security and data-governance practices.
  • Must be permanently authorized to work in the United States and must not require employment visa sponsorship now or in the future; students on CPT, OPT, or STEM OPT are ineligible unless they have an alternative long-term status that does not require company sponsorship.
Responsibilities
  • Conduct supervised laboratory walkthroughs to develop and maintain an accurate inventory of automation systems, components, software, locations, system owners, operational status, and scientific use cases.
  • Reconcile field observations with existing records and work with system owners to identify and resolve missing, duplicate, or inconsistent information.
  • Learn automation platform purpose, operating sequences, inputs, outputs, interfaces, dependencies, and supporting scientific workflows through supervised shadowing.
  • Collect, review, and organize technical documentation, including equipment manuals, configuration records, setup instructions, deck layouts, integration notes, and service documentation.
  • Apply consistent naming conventions and metadata to improve the organization, standardization, and searchability of automation-related information.
  • Identify and define potential Large Language Model use cases for record classification, metadata extraction, setup summarization, missing-data detection, and other knowledge-management needs.
  • Document AI use-case objectives, intended users, data inputs, expected outputs, assumptions, risks, success criteria, and human-review requirements.
  • Evaluate the feasibility of proposed Large Language Model use cases using approved tools and verified information.
  • Support automation system assessments, demonstrations, data cleanup, reporting, issue tracking, project coordination, and knowledge-transfer activities.
  • Develop standardized automation system profiles and support creation of an organized, searchable repository of equipment and technical information.
  • Prepare project documentation and a final stakeholder presentation summarizing completed work, findings, identified gaps, and recommendations.
  • Follow applicable laboratory safety, EH&S, cybersecurity, data-handling, responsible AI, access-control, and equipment-specific requirements.
Desired Qualifications
  • Interest or experience with laboratory automation systems, robotics, automation software, or scientific instrumentation.
  • Familiarity with automation system components, equipment interfaces, laboratory workflows, or scientific technology.
  • Exposure to asset-management systems, service platforms, or technical equipment databases.
  • Experience organizing or documenting technical systems, equipment, or workflows.
  • Experience using Excel, SharePoint, and Microsoft Teams to organize, review, or maintain technical information.
  • Familiarity with data cleanup, data validation, reconciliation, metadata, record classification, or structured information management.
  • Experience working with equipment documentation, manuals, configuration records, setup instructions, or other technical information.
  • Interest or experience in knowledge management and improving the accessibility, consistency, and usability of technical information.
  • Interest or experience with Large Language Models, Generative AI, prompt design, or responsible AI.
  • Familiarity with using approved AI tools for information classification, metadata extraction, summarization, or missing-data identification.
  • Understanding of the importance of data quality, information security, human review, and responsible use of AI-generated outputs.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.